FDA grants fast track designation for Anthos’ cancer associated thrombosis therapy

The US Food and Drug Administration (FDA) has granted fast track designation for Anthos Therapeutics’ investigational Factor XI inhibitor, abelacimab, to treat thrombosis associated with cancer.